{"id":"nifuroxazide","rwe":[{"pmid":"41830696","year":"2026","title":"Mapping the landscape of online antibiotic sellers in Indonesia: A study on distribution, regulation, and public health risks.","finding":"","journal":"Public health","studyType":"Clinical Study"},{"pmid":"41771784","year":"2026","title":"Molecular Docking, DFT, and Structural Characterization of Cr(III), Mn(II), and Fe(III) Mixed-Ligand Complexes With Nifuroxazide and 4-Chloro-Pyridine-2-Carboxylic Acid: New Perspectives on Antibacterial and Anti-Inflammatory Activity.","finding":"","journal":"Chemistry & biodiversity","studyType":"Clinical Study"},{"pmid":"41770503","year":"2026","title":"Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review.","finding":"","journal":"Inflammopharmacology","studyType":"Clinical Study"},{"pmid":"41731511","year":"2026","title":"Macrophage-delivered Nifuroxazide reprograms immunosuppressive microenvironment and synergizes with oxaliplatin for enhanced anti-hepatocellular carcinoma therapy.","finding":"","journal":"Journal of nanobiotechnology","studyType":"Clinical Study"},{"pmid":"41685604","year":"2026","title":"Regorafenib and Nifuroxazide exert enhanced suppression of hepatocellular carcinoma by inhibiting STAT3 and immune remodeling.","finding":"","journal":"Oncology reports","studyType":"Clinical Study"}],"tags":[{"label":"nifuroxazide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Signal transducer and activator of transcription 3","category":"target"},{"label":"STAT3","category":"gene"},{"label":"A07AX03","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":169.733,"date":"","count":19,"signal":"Trimethylaminuria","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=170)"},{"llr":110.721,"date":"","count":20,"signal":"Pseudomembranous colitis","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=111)"},{"llr":105.489,"date":"","count":18,"signal":"Megacolon","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=105)"},{"llr":83.455,"date":"","count":13,"signal":"Dysbiosis","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=83)"},{"llr":79.792,"date":"","count":19,"signal":"Intestinal perforation","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=80)"},{"llr":76.977,"date":"","count":20,"signal":"Peritonitis","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=77)"},{"llr":73.072,"date":"","count":21,"signal":"Clostridium difficile infection","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=73)"}],"commonSideEffects":[{"effect":"Trimethylaminuria","drugRate":"LLR 170","severity":"common"},{"effect":"Pseudomembranous colitis","drugRate":"LLR 111","severity":"common"},{"effect":"Megacolon","drugRate":"LLR 105","severity":"common"},{"effect":"Dysbiosis","drugRate":"LLR 83","severity":"common"},{"effect":"Intestinal perforation","drugRate":"LLR 80","severity":"common"},{"effect":"Peritonitis","drugRate":"LLR 77","severity":"common"},{"effect":"Clostridium difficile infection","drugRate":"LLR 73","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dicoferin","offLabel":[],"synonyms":["nifuroxazide","dicoferin","nifuroxazid","pentofuryl"],"timeline":[],"approvals":[],"brandName":"Dicoferin","ecosystem":[],"mechanism":{"target":"Signal transducer and activator of transcription 3","targets":[{"gene":"STAT3","source":"DrugCentral","target":"Signal transducer and activator of transcription 3","protein":"Signal transducer and activator of transcription 3"}],"modality":"Small Molecule","drugClass":"nifuroxazide","explanation":"Think of STAT3 like a messenger that helps cells respond to signals. When it's overactive, it can lead to inflammation and other problems. Dicoferin blocks this messenger, which can help reduce inflammation and other symptoms.","oneSentence":"Dicoferin works by inhibiting the activity of STAT3, a protein involved in cell signaling and inflammation.","technicalDetail":"Dicoferin specifically binds to the SH2 domain of STAT3, preventing its phosphorylation and subsequent dimerization, which are essential steps in the activation of STAT3."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1928","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NIFUROXAZIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIFUROXAZIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:57:48.705135","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:38:59.607850+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"digitoxin","drugSlug":"digitoxin","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"digoxin","drugSlug":"digoxin","fdaApproval":"1975-10-24","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"levomenol","drugSlug":"levomenol","fdaApproval":"","relationship":"same-target"},{"drugName":"niclosamide","drugSlug":"niclosamide","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"nitazoxanide","drugSlug":"nitazoxanide","fdaApproval":"2002-11-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"nifuroxazide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"digitoxin","brandName":"digitoxin","genericName":"digitoxin","approvalYear":"","relationship":"same-target"},{"drugId":"digoxin","brandName":"digoxin","genericName":"digoxin","approvalYear":"1975","relationship":"same-target"},{"drugId":"levomenol","brandName":"levomenol","genericName":"levomenol","approvalYear":"","relationship":"same-target"},{"drugId":"niclosamide","brandName":"niclosamide","genericName":"niclosamide","approvalYear":"","relationship":"same-target"},{"drugId":"nitazoxanide","brandName":"nitazoxanide","genericName":"nitazoxanide","approvalYear":"2002","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05754996","phase":"PHASE3","title":"Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-03-12","conditions":["Hepatic Encephalopathy"],"enrollment":80,"completionDate":"2025-07-29"},{"nctId":"NCT05988528","phase":"PHASE2,PHASE3","title":"Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2023-08-20","conditions":["Inflammatory Bowel Diseases"],"enrollment":50,"completionDate":"2025-02-20"},{"nctId":"NCT06368869","phase":"NA","title":"The Effect of Different Types of Resin Cements on the Color Stability of Two Different Types of Ceramic Veneers","status":"COMPLETED","sponsor":"amr elshimy","startDate":"2023-01-10","conditions":["Color; Change Teeth, Posteruptive"],"enrollment":44,"completionDate":"2024-01-20"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005828","UNII":"PM5LI0P38J","CHEBI":"CHEBI:135136","INN_ID":"1578","RXNORM":"31782","UMLSCUI":"C0068742","ChEMBL_ID":"CHEMBL244888","KEGG_DRUG":"D07111","DRUGBANK_ID":"DB13855","PUBCHEM_CID":"5337997","SNOMEDCT_US":"703471002","IUPHAR_LIGAND_ID":"12358","MESH_SUPPLEMENTAL_RECORD_UI":"C013150"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":191,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A07AX03","allCodes":["A07AX03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 13","pmid":"41830696","title":"Mapping the landscape of online antibiotic sellers in Indonesia: A study on distribution, regulation, and public health risks.","journal":"Public health"},{"date":"2026 Mar","pmid":"41771784","title":"Molecular Docking, DFT, and Structural Characterization of Cr(III), Mn(II), and Fe(III) Mixed-Ligand Complexes With Nifuroxazide and 4-Chloro-Pyridine-2-Carboxylic Acid: New Perspectives on Antibacterial and Anti-Inflammatory Activity.","journal":"Chemistry & biodiversity"},{"date":"2026 Mar 2","pmid":"41770503","title":"Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review.","journal":"Inflammopharmacology"},{"date":"2026 Feb 23","pmid":"41731511","title":"Macrophage-delivered Nifuroxazide reprograms immunosuppressive microenvironment and synergizes with oxaliplatin for enhanced anti-hepatocellular carcinoma therapy.","journal":"Journal of nanobiotechnology"},{"date":"2026 Apr","pmid":"41685604","title":"Regorafenib and Nifuroxazide exert enhanced suppression of hepatocellular carcinoma by inhibiting STAT3 and immune remodeling.","journal":"Oncology reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:38:59.607850+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}